Guardant Health reported second quarter 2026 financial results with total revenue of $335.0 million, a 44% increase from the prior year period. Oncology revenue grew 38% to $219.1 million, driven by a 63% rise in test volume to approximately 104,000 tests. Screening revenue surged over 250% to $52.9 million as Shield test volume reached 66,000. The company raised its full-year 2026 revenue guidance to $1.34–$1.36 billion, reflecting expected growth of 36% to 38%. Guardant Health operates in the precision oncology industry, providing blood and tissue tests for cancer screening, monitoring, and treatment selection.